

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



National  
Library  
of Medicine

|        |            |   |        |   |  |   |   |   |   |  |
|--------|------------|---|--------|---|--|---|---|---|---|--|
| PubMed | Nucleotide | Protein   | Genome | Structure   | PMC  | Taxonomy  | OMIM  | Books   |   |  |
| Search | PubMed     | <input style="width: 15px; height: 15px; vertical-align: middle;" type="button" value="▼"/> | for    |   |  |   |   | <input style="width: 40px; height: 20px; vertical-align: middle;" type="button" value="Go"/>      | <input style="width: 40px; height: 20px; vertical-align: middle;" type="button" value="Clear"/> |  |
|        |            |   |        | <input style="width: 40px; height: 20px; vertical-align: middle;" type="button" value="Limits"/>  | <input style="width: 100px; height: 20px; vertical-align: middle;" type="button" value="Preview/Index"/> | <input style="width: 80px; height: 20px; vertical-align: middle;" type="button" value="History"/> | <input style="width: 80px; height: 20px; vertical-align: middle;" type="button" value="Clipboard"/> | <input style="width: 80px; height: 20px; vertical-align: middle;" type="button" value="Details"/> |   |  |
|        |            |   |        | <input style="width: 40px; height: 20px; vertical-align: middle;" type="button" value="Display"/> <input style="width: 40px; height: 20px; vertical-align: middle;" type="button" value="Abstract"/> <input style="width: 15px; height: 15px; vertical-align: middle;" type="button" value="▼"/> Show: 20 <input style="width: 15px; height: 15px; vertical-align: middle;" type="button" value="▼"/> Sort <input style="width: 15px; height: 15px; vertical-align: middle;" type="button" value="▼"/> Send to <input style="width: 40px; height: 20px; vertical-align: middle;" type="button" value="Text"/> <input style="width: 15px; height: 15px; vertical-align: middle;" type="button" value="▼"/> |  |   |   |   |   |  |

Entrez  
PubMed

1: Cancer Res. 1998 May 1;58(9):1965-71.

[Related Articles](#), [Links](#)

Comment in:

- [Cancer Res. 1999 Sep 1;59\(17\):4471-2.](#)

## DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors.

PubMed  
Services

**Chen Y, Hu D, Eling DJ, Robbins J, Kipps TJ.**

University of California at San Diego Human Gene Therapy Program, Department of Medicine, University of California at San Diego School of Medicine, La Jolla 92093-0663, USA.

Related  
Resources

We generated DNA expression vectors encoding the full-length neu cDNA (designated pNeuN), the neu extracellular domain (pNeuE), or the neu extracellular and transmembrane domains (pNeuTM). The 293 cells transfected with pNeuN or pNeuTM expressed the neu extracellular domain on the surface membrane, whereas 293 cells transfected with pNeuE secreted the extracellular domain of neu into the culture supernatant. We examined whether i.m. injection of either of these plasmids could induce protective immunity in FVB/N mice against the adoptive transfer of Tgl-1 cells, a neu-expressing tumor cell line generated from a mouse mammary tumor that spontaneously arose in a FVB/N neu-transgenic mouse. The i.m. injection of pNeuTM or pNeuE, and to a lesser extent pNeuN, induced protective immunity against a subsequent challenge with Tgl-1 cells in FVB/N mice. In addition, the coinjection of a plasmid encoding interleukin-2 (designated pIL-2) augmented the efficacy of each of the pNeu plasmids for inducing protective immunity. The plasmid pNeuTM seemed to be the most effective for inducing anti-neu antibodies. However, the generation of detectable anti-neu antibodies in response to any one of these pNeu plasmids was not enhanced by coinjection of pIL-2 and was not required for protective immunity against Tgl-1 cells. These studies demonstrate that DNA expression vectors encoding soluble or membrane-bound forms of neu lacking the cytoplasmic kinase domain can be effective in inducing protective antitumor immunity.

PMID: 9581840 [PubMed - indexed for MEDLINE]

|   |  |   |          |   |      |   |   |  |   |
|---|--|---|----------|---|------|---|---|--|---|
| <input style="width: 40px; height: 20px; vertical-align: middle;" type="button" value="Display"/> | <input style="width: 40px; height: 20px; vertical-align: middle;" type="button" value="Abstract"/> | <input style="width: 15px; height: 15px; vertical-align: middle;" type="button" value="▼"/> | Show: 20 | <input style="width: 15px; height: 15px; vertical-align: middle;" type="button" value="▼"/> | Sort | <input style="width: 15px; height: 15px; vertical-align: middle;" type="button" value="▼"/> | <input style="width: 40px; height: 20px; vertical-align: middle;" type="button" value="Send to"/> | <input style="width: 40px; height: 20px; vertical-align: middle;" type="button" value="Text"/> | <input style="width: 15px; height: 15px; vertical-align: middle;" type="button" value="▼"/> |
|---|--|---|----------|---|------|---|---|--|---|



|               |                          |         |               |           |           |          |       |       |
|---------------|--------------------------|---------|---------------|-----------|-----------|----------|-------|-------|
| PubMed        | Nucleotide               | Protein | Genome        | Structure | PMC       | Taxonomy | OMIM  | Books |
| Search PubMed | <input type="text"/> for |         |               |           |           | Go       | Clear |       |
|               |                          | Limits  | Preview/Index | History   | Clipboard | Details  |       |       |
|               |                          | Display | Abstract      | Show: 20  | Sort      | Send to  | Text  |       |

Entrez  
PubMed

PubMed  
Services

Related  
Resources

□1: Cancer Res. 1998 Nov 1;58(21):4902-8.

Related Articles, Links

**Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.**

**Zaks TZ, Rosenberg SA.**

Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892-1502,  
USA. zakst@nih.gov

The oncogene HER-2/neu is genetically amplified and overexpressed in a large number of human adenocarcinomas and has been implicated in the tumorigenic phenotype. Although it is a nonmutated self-protein, it is barely detectable in adult tissues, and immune responses toward it have been described in a number of patients. It is, thus, an attractive candidate antigen for the immunotherapy of cancer patients. HLA-A2+ patients with metastatic breast, ovarian, or colorectal adenocarcinomas that overexpressed HER-2/neu were immunized with the HLA-A2-binding epitope p369-377 (p369). Patients were treated by repeated immunization with 1 mg of p369 in Freund's incomplete adjuvant every 3 weeks. Peripheral blood mononuclear cells were collected prior to immunization and following two and four immunizations and were stimulated in vitro with peptide and assayed for peptide and tumor recognition. In three of four patients, peptide-specific CTLs were detected in post- but not preimmunization blood. These CTLs recognized peptide-pulsed target cells at peptide concentrations of > or = 1 ng/ml yet failed to react with a panel of HLA-A2+ HER-2/neu+ tumor lines. In addition, infecting HLA-A2+ cells with recombinant vaccinia virus encoding HER-2/neu or up-regulating HLA-A2 with IFN-gamma in HER-2/neu+ cells also failed to confer reactivity by p369-reactive T-cells. A T-cell response to the HLA-A2 binding epitope p369 can be easily generated by immunizing patients with peptide in Freund's incomplete adjuvant. However, the CTLs failed to react with HER-2/neu+ tumor cells. Further studies are needed to determine whether and how HER-2 might serve as an antigen for tumor immunotherapy.

PMID: 9809997 [PubMed - indexed for MEDLINE]

|         |          |          |      |         |      |
|---------|----------|----------|------|---------|------|
| Display | Abstract | Show: 20 | Sort | Send to | Text |
|---------|----------|----------|------|---------|------|



National  
Library  
of Medicine

PubMed Nucleotide Protein Genome Structure PMC Taxonomy OMIM Books

Search PubMed  for

Entrez  
PubMed

1: *Surgery*. 1997 Aug;122(2):235-41; discussion 241-2.

## Generation of peptide-specific cytotoxic T lymphocytes using allogeneic dendritic cells capable of lysing human pancreatic cancer cells.

Peiper M, Goedegebuure PS, Eberlein TJ.

PubMed  
Services


Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass. 02115, USA.

Related  
Resources

**BACKGROUND:** Dendritic cells (DCs) are potent antigen presenting cells (APCs), able to efficiently induce primary T cell-mediated responses to foreign antigens. In earlier studies we were able to identify a histocompatibility antigen (HLA)-A 2-restricted nine amino acid peptide (GP2, peptide 654-662) from the transmembrane portion of the protooncogene HER2/neu as a tumor-associated antigen (TAA) in human pancreatic cancer. **METHODS:** Peripheral blood mononuclear cells (PBMCs) of HLA-A2+ and HLA-A2 healthy volunteers were isolated. PBMCs were grown with initial anti-CD3, low-dose interleukin-2 (IL-2), and peptide-pulsed DC stimulation. T-cell lines were analyzed in functional studies. **RESULTS:** After 4 weeks, T-cell cultures were more than 50% CD8+. All peptide-pulsed T cells significantly lysed APC pulsed with the immunizing antigen in an HLA-A2 restricted fashion. Furthermore, HLA-A2+,HER2/neu+ human pancreatic cancer cells were lysed significantly higher than HLA-A2 HER2/neu+ pancreatic cancer cells. Transfection of an HLA-A2 pancreatic cancer cell line with the HLA-A2 gene resulted in a significantly higher lysis of the transfected cell line compared to the wild type. In HLA-A2+ pancreatic cancer targets, specific lysis was HLA-A2 restricted. **CONCLUSION:** The ability to use DCs for presentation of either tumor or peptide antigen in an HLA-restricted fashion to stimulate T-cell proliferation, as well as cytotoxicity, demonstrates the potential of this technology for future development of a pancreatic cancer vaccine.

PMID: 9288128 [PubMed - indexed for MEDLINE]

[Write to the Help Desk](#)  
NCBI | NLM | NIH



|               |                                |               |         |           |         |          |       |              |     |
|---------------|--------------------------------|---------------|---------|-----------|---------|----------|-------|--------------|-----|
| PubMed        | Nucleotide                     | Protein       | Genome  | Structure | PMC     | Taxonomy | OMIM  | Books        |     |
| Search PubMed | <input type="text"/> for " [▼] |               |         |           |         | Go       | Clear |              |     |
|               | Limits                         | Preview/Index | History | Clipboard | Details |          |       |              |     |
|               | Display Abstract               |               | [▼]     | Show: 20  | [▼]     | Sort     | [▼]   | Send to Text | [▼] |

Entrez  
PubMed

□1: J Immunol. 1994 Nov 15;153(10):4775-87.

Related Articles, Links

**Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor.**

**Chen TT, Tao MH, Levy R.**

PubMed  
Services

Department of Medicine, School of Medicine, Stanford University, CA 94305.

Related  
Resources

Idiotypic determinants, antigenic sites expressed on the variable region of Ig molecules of malignant B cells, represent tumor-specific Ags but are weak immunogens. We have previously shown that the immunogenicity can be dramatically increased by fusing tumor Id to granulocyte macrophage (GM)-CSF. Here, we demonstrate that fusion proteins with IL-2 or IL-4 can also be highly immunogenic. Co-immunization of these fusion proteins with another Id demonstrated the importance of physical linkage between the cytokine and relevant Ag for this enhancement. All three fusion proteins are capable of eliciting significant levels of specific Abs against the Id without the use of carrier proteins or adjuvants, although the GM-CSF fusion protein appeared to be unique in its ability to induce higher titers of anti-Id Abs in the primary response. Furthermore, the Id-IL-2 fusion protein induced high titers of IgG2a and IgG3 anti-Id Abs, whereas the Id-IL-4 and Id-GM-CSF fusion proteins did not. Despite the differences, tumor protection was comparable in all mice having significant titers of anti-Id Abs, regardless of the fusion protein used. We concluded that Id-cytokine fusion proteins are potent immunogens that can elicit significant antitumor immunity. The general approach of fusing a cytokine to a potential Ag may be applicable to the design of vaccines for immunotherapy of other types of tumors as well as for other pathogens and disease states.

PMID: 7525715 [PubMed - indexed for MEDLINE]

|         |          |     |          |     |      |     |         |      |     |
|---------|----------|-----|----------|-----|------|-----|---------|------|-----|
| Display | Abstract | [▼] | Show: 20 | [▼] | Sort | [▼] | Send to | Text | [▼] |
|---------|----------|-----|----------|-----|------|-----|---------|------|-----|

[Write to the Help Desk](#)

[NCBI | NLM | NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act | Disclaimer](#)

**WEST** [Generate Collection](#) [Print](#)

L6: Entry 10 of 15

File: USPT

Apr 3, 2001

DOCUMENT-IDENTIFIER: US 6210662 B1  
TITLE: Immunostimulatory composition

Brief Summary Text (4):

The immune response of the mammalian immune system is generally divided into two general types: humoral immunity, mediated largely by circulating antibodies, and cellular immunity mediated by various forms of T-cells. Generally, extracellular antigens stimulate a humoral response, while intracellular antigens such as viruses, stimulate a cellular response.

Brief Summary Text (23):

In further related aspects, the invention also includes expression vectors and expression systems for producing the above-described immunostimulatory fusion proteins, as well as substantially purified nucleic acid molecules that encode such fusion proteins. In preferred embodiments, the nucleic acid molecules code for fusion proteins consisting essentially of GM-CSF and prostatic acid phosphatase or of GM-CSF and Her2.

Drawing Description Text (9):

FIG. 8 shows the nucleic acid (SEQ ID NO: 3) and amino acid (SEQ ID NO: 4) sequences of a GM-CSF-Her2 fusion protein in accordance with the present invention.

Detailed Description Text (32):

Fusion proteins constructed to incorporate oncogene product antigens are exemplified by incorporation of the oncogene product Her2. Her2 is a growth factor receptor belonging to the EGF-R family of receptors. It is overexpressed by breast cancer cells, ovarian cancer cells and a variety of other cancer cells. The cDNA coding for the extracellular domain of Her2 is cloned from a breast cancer cell line and fused to the GM-CSF cDNA, essentially as detailed for PAP-GM-CSF, above.

Detailed Description Text (33):

Production of the soluble protein can be verified using Her2-specific monoclonal antibodies in an ELISA test, according to methods well-known in the art. The fusion protein includes the sequences for the extracellular domain (amino acids 1-652) of Her2 (GenBank) and GM-CSF (FIG. 8). In this particular fusion protein the two proteins are linked by a leucine/glutamic acid linker which is generated by inserting a XhoI site. Other oncogene product antigens are similarly incorporated into fusion proteins according to the methods described herein, using published sequences. In addition, other antigens, such as viral antigens, may be part of a fusion construct, according to the methods described herein.

**WEST**
  

L9: Entry 9 of 14

File: USPT

Apr 3, 2001

US-PAT-NO: 6210662  
 DOCUMENT-IDENTIFIER: US 6210662 B1

TITLE: Immunostimulatory composition

DATE-ISSUED: April 3, 2001

## INVENTOR-INFORMATION:

| NAME                 | CITY       | STATE | ZIP CODE | COUNTRY |
|----------------------|------------|-------|----------|---------|
| Laus; Reiner         | San Carlos | CA    |          |         |
| Ruegg; Curtis Landon | San Carlos | CA    |          |         |
| Wu; Hongyu           | Palo Alto  | CA    |          |         |

## ASSIGNEE-INFORMATION:

| NAME                 | CITY    | STATE | ZIP CODE | COUNTRY | TYPE CODE |
|----------------------|---------|-------|----------|---------|-----------|
| Dendreon Corporation | Seattle | WA    |          |         | 02        |

APPL-NO: 09/ 344195 [PALM]  
 DATE FILED: June 24, 1999

## PARENT-CASE:

This application is a continuation of U.S. patent application Ser. No. 09/146,283, filed Sep. 3, 1998, now granted as U.S. Pat. No. 5,976,546, which is a divisional of U.S. patent application Ser. No. 08/579,823, filed Dec. 28, 1995 now granted as U.S. Pat. No. 6,080,409, both of which are herein incorporated by reference.

INT-CL: [07] A01 N 63/00, A01 N 65/00, C12 N 5/00, C12 N 5/08

US-CL-ISSUED: 424/93.1; 435/325, 435/366, 435/372, 435/372.3  
 US-CL-CURRENT: 424/93.1; 435/325, 435/366, 435/372, 435/372.3

FIELD-OF-SEARCH: 424/93.1, 435/325, 435/366, 435/372, 435/372.3

## PRIOR-ART-DISCLOSED:

## U.S. PATENT DOCUMENTS

| PAT-NO                                  | ISSUE-DATE   | PATENTEE-NAME     | US-CL |
|---|--------------|-------------------|-------|
| <input type="checkbox"/> <u>4861589</u> | August 1989  | Ju                |       |
| <input type="checkbox"/> <u>5019384</u> | May 1991     | Gefter et al.     |       |
| <input type="checkbox"/> <u>5078996</u> | January 1992 | Colon, III et al. |       |
| <input type="checkbox"/> <u>5194254</u> | March 1993   | Barber et al.     |       |
| <input type="checkbox"/> <u>5616477</u> | April 1997   | Price             |       |
| <input type="checkbox"/> <u>5677171</u> | October 1997 | Hudziak et al.    |       |

## FOREIGN PATENT DOCUMENTS

| FOREIGN-PAT-NO | PUBN-DATE      | COUNTRY | US-CL |
|----------------|----------------|---------|-------|
| 0 406 857 A1   | January 1991   | EP      |       |
| WO 91/13632    | September 1991 | WO      |       |
| WO 93/20185    | October 1993   | WO      |       |
| WO 94/17192    | August 1994    | WO      |       |
| WO 94/21287    | September 1994 | WO      |       |
| WO 95/21862    | August 1995    | WO      |       |
| WO 95/23814    | September 1995 | WO      |       |
| WO 95/34638    | December 1995  | WO      |       |

## OTHER PUBLICATIONS

- Berzofsky, J.A., and Berkower, I.J., "Immunogenicity and Antigen Structure," in Fundamental Immunology, Third Edition (Paul, W.E., Ed.) Raven Press, Ltd., New York, NY, pp. 235-274 (1993).
- Disis, M.L., et al., "Peptide-Based, but Not Whole Protein, Vaccines Elicit Immunity to HER-2/neu, an Oncogenic Self-Protein," *J. Immunol.* 156:3151-3158 (1996).
- Fisk, B., et al., "Identification of Immunodominant Peptide of HER-2/neu Protooncogene Recognized by Ovarian Tumor-Specific Cytotoxic T Lymphocyte Lines," *J. Exp. Med.* 181:2109-2117 (1995).
- Flamand, V., et al., "Murine Dendritic Cells in Vitro with Tumor Antigen Induce Tumor Resistance in Vivo," *Eur. J. Immunol.* 24:605-610 (1994).
- Lin, R. -H., et al., "Induction of Autoreactive B Cells Allows Priming of Autoreactive T Cells," *J. Exp. Med.* 173:1433-1439 (1991).
- Mamula, M.J., et al., "Breaking T Cell Tolerance with Foreign and Self Co-Immunogens," *J. Immunol.* 149 (3) : 789-795 (1992).
- Schirmbeck, R., et al., "Immunization of Mice with the N-Terminal (1-272) Fragment of Simian Virus 40 Large T Antigen (Without Adjuvants) Specifically Primes Cytotoxic T Lymphocytes," *Eur. J. Immunol.* 23:1528-1534 (1993).
- Schwartz, R.H., "Immunological Tolerance," in Fundamental Immunology, Third Edition (Paul, W.E., Ed.) Raven Press, Ltd., New York, NY, pp. 677-720 (1993).
- Tao, M.-H., and Levy, R., "Idiotype/Granulocyte-Macrophage Colony-Stimulating Factor Fusion Protein as a Vaccine for B-Cell Lymphoma," *Nature* 362:755 (1993).
- Sharief, F.S., et al., "Human Prostatic Acid Phosphatase:cDNA Cloning, Gene Mapping and Protein Sequence Homology with Lysosomal Acid Phosphatase," *Biochemical and Biophysical Research Communications*, 160(1) : 79-86 (1989).
- Stauss H.J., et al., "Induction of Cytotoxic T Lymphocytes with Peptides in vitro: Identification of Candidate T-cell Epitopes in Human Papilloma Virus," *Proc. Natl. Acad. Sci. USA*, 89:7871-7875 (1992).
- Takahashi, H., et al., "Induction of CD8.sup.+ Cytotoxic T Cells by Immunization with Purified HIV-1 Envelope Protein in ISCOMs," *Nature*, 344:873-875 (1990).

ART-UNIT: 165

PRIMARY-EXAMINER: Navarro; Albert

ATTY-AGENT-FIRM: Judge; Linda R. Iota Pi Law Group

## ABSTRACT:

Disclosed are therapeutic compositions and methods for inducing cytotoxic T cell responses in vitro and in vivo. The therapeutic compositions consist of antigen presenting cells activated by contact with a polypeptide complex constructed by joining together a dendritic cell-binding protein and a polypeptide antigen. Also disclosed are expression vectors and systems for producing the polypeptide complexes.

3 Claims, 9 Drawing figures

## WEST

 Generate Collection 

L9: Entry 9 of 14

File: USPT

Apr 3, 2001

DOCUMENT-IDENTIFIER: US 6210662 B1  
TITLE: Immunostimulatory composition

Brief Summary Text (14):

These limitations are overcome by the discovery encompassed by the present invention. It is the discovery of the present invention that a T-cell response, and specifically, an MHC-Class I mediated T-cell response, can be stimulated by an isolated or soluble protein, when it is presented to the immune system as part of a complex with a dendritic cell binding protein, and more particularly GM-CSF. It is the further discovery of the present invention that such a response can be stimulated *in vitro*. As discussed above, *in vitro* stimulation of such a response has not previously been demonstrated using a full-length soluble antigen. The present invention provides for induction by isolated or soluble proteins of cellular immunity *in vitro* by presenting a specific antigen to an antigen presenting cell (APC), such as a dendritic cell, as part of an immunogenic fusion protein.

Brief Summary Text (15):

An important aspect of the present invention is the choice of fusion partner protein, a dendritic cell binding protein, such as granulocyte-macrophage colony stimulating protein (GM-CSF). Without relying on any particular mechanistic theory, it is believed that the protein antigen is transported over the plasma membrane of the APC in a receptor mediated non-disruptive way. It is further believed that the dendritic cell binding portion of the fusion protein serves to preserve the viability and functionality of the APC.

Detailed Description Text (39):

The use as APC's of dendritic cells stimulated by GM-CSF fusion antigens yields superior results to other approaches such as peptide pulsed dendritic cells. It is known that dendritic cells pulsed with 8-11-mer peptides induce immunity that is directed to a single T-cell epitope. Proteins incorporated into liposomes or delivered by osmotic shock induce reactivity towards multiple T-cell epitopes; however, this process is relatively ineffective due to the inherent toxicity of these treatments to dendritic cells. GM-CSF fusion antigens of the present invention, on the other hand, induce immunity towards multiple epitopes and preserve and enhance at the same time viability and function of the dendritic cell.

Detailed Description Text (41):

In experiments carried out in support of the present invention, the fusion protein consisting of PAP and GM-CSF described in the previous section was used for *in vitro* introduction to dendritic cells and subsequent activation of cytolytic T cells, as detailed in Example 4. Briefly, HLA-A2.1 positive PBMNC were isolated by standard methods and primed with the fusion protein for 2-5 days. The cell mixture was depleted of CD4<sup>+</sup> T-cells, separated into high and low density fractions, and the separate cultures were restimulated weekly with autologous PAP GM-CSF pulsed APC's. Lytic potential of the T-cells present in the fractions was assessed using a standard chromium release assay using an HLA-A2.1-transgenic prostate carcinoma cell line as target. This novel cell line was constructed according to the methods detailed in Example 3 herein and is useful in screening and analysis of HLA class I restricted cytotoxic T-lymphocytes.

Detailed Description Text (48):

In practice, dendritic cells are isolated from an individual, using known methods, or preferably, as described in Example 5. The dendritic cells (or other APC's) are mixed

with 10 ng/ml equivalent of GM-CSF fusion antigen, as described in Example 4. The cell preparation may then be depleted of CD4<sup>+</sup> T-cells by solid phase immunoabsorption and further fractionated to enrich for cells having cytolytic activity. Doses of about 10.<sup>sup.7</sup> cells are then administered to the subject by intravenous or central injection according to established procedures (e.g., infusion over 30 to 60 minutes). The responsiveness of the subject to this treatment is measured by monitoring the induction of a cytolytic T-cell response, a helper T-cell response and antibody response towards the antigen in peripheral blood mononuclear cells by methods well known in the art.

**WEST** [Generate Collection](#) [Print](#)

L22: Entry 24 of 29

File: USPT

Apr 9, 2002

DOCUMENT-IDENTIFIER: US 6368796 B1

\*\* See image for Certificate of Correction \*\*

TITLE: Methods of detection and treatment of breast cancer

Detailed Description Text (86):

ErbB-2 functions as a co-receptor for growth-regulatory molecules, including neuregulins. Replacement of the extracellular domain of ErbB-2 by the ligand biding domain of the receptor for EGF allows heterologous stimulation of the ErbB-2, which has been successfully exploited in signal transduction studies (Ben-Levy, R., et al., EMBO J., 13;3302-3311 (1994)). The transforming protein of ErbB-2, which contains a Glutamine residue (Glu.<sup>664</sup>) instead of a Valine (VAL.<sup>664</sup>) residue, is a constitutively active receptor permanently coupled to signaling pathways. To confirm that the association of CHK with ErbB-2 is mediated by the intracellular domain of ErbB-2 and not by other members of the ErbB-2 family, chimeric proteins that include the extracellular domain of the EGF receptor and the transmembrane and cytoplasmic domains of the ErbB-2, terminated NEC (Val.<sup>664</sup>), or the point-mutated cytoplasmic domain of ErbB-2 (Glu.<sup>664</sup>) terminated TEC, (kindly obtained from Dr. Y. Yarden (Department of Chemical Immunology, the Weizmann Institute of Science, Rehovot, Israel); Peles, E., et al., J. Biol. Chem., 267:12266-12274 (1992)) were used in this study. It is Important to note that ErbB-2 does not directly bind to any of the EGF-like ligands. However, EGF and HRG induce the tyrosine phosphorylation of ErbB-2, presumably by ligand-driven heterodimerization and transphosphorylation. NIH3T3 cells were stably transfected with the chimeric plasmid EGF-TEC-ErbB-2 or with the chimeric plasmid EGF-NEC-ErbB-2. TEC and NEC cells (4.times.10.<sup>6</sup> cells/plate) were serum-starved and then unstimulated or stimulated with 100 ng EGF at room temperature for 5 minutes. The lysates were divided to two parts: one half of the lysates were precipitated with the CHK-SH2 GST-fusion protein (10 .mu.g) for 90 minutes at 4.degree. C. (A-II, B-II). After washing, the precipitates were separated by 7% SDS-PAGE and immunoblotted with monoclonal anti-phosphotyrosine antibody (PY20), or with polyclonal anti-EGF-R antibodies. The other half of the lysates was immunoprecipitated using monoclonal antibodies for EGF-R for 16 h at 4.degree. C. The washed precipitates were run on 7% SDS-PAGE and blotted with PY20 or with anti-EGF-R antibodies.

**WEST****End of Result Set** [Generate Collection](#) [Print](#)

L10: Entry 2 of 2

File: USPT

Jan 25, 2000

US-PAT-NO: 6017527

DOCUMENT-IDENTIFIER: US 6017527 A

TITLE: Activated dendritic cells and methods for their activation

DATE-ISSUED: January 25, 2000

## INVENTOR-INFORMATION:

| NAME                | CITY    | STATE | ZIP CODE | COUNTRY |
|---------------------|---------|-------|----------|---------|
| Maraskovsky; Eugene | Seattle | WA    |          |         |
| Mc Kenna; Hilary J. | Seattle | WA    |          |         |

US-CL-CURRENT: 424/93.71; 424/93.7, 435/2, 435/325, 435/375, 435/377, 435/455

## CLAIMS:

What is claimed is:

1. A method of stimulating an immune response specific for an antigen in an individual, comprising the steps of:

(a) obtaining dendritic cells from the individual;

(b) transfecting the dendritic cells with a gene encoding the antigen;

(c) activating the transfected dendritic cells by exposing them to a CD40 binding protein capable of binding CD40 and inhibiting binding of CD40 to CD40L, as determined by observing at least about 90% inhibition of the binding of soluble CD40 to CD40L; and,

(d) administering the activated, antigen-expressing dendritic cells to the individual.

2. The method according to claim 1, wherein the dendritic cells are obtained by obtaining hematopoietic stem or progenitor cells from the individual, and contacting the hematopoietic stem or progenitor cells with a molecule selected from the group consisting of flt-3 ligand, GM-CSF, IL-4, TNF-.alpha., IL-3, c-kit ligand, fusions of GM-CSF and IL-3, and combinations thereof.

3. The method according to claim 2, wherein the CD40 binding protein comprises an oligomer forming peptide and soluble, oligomeric CD40 ligand, wherein the soluble, oligomeric CD40 ligand comprises a polypeptide selected from the group consisting of:

(a) a polypeptide comprising amino acids 1 through 261, 35 through 261, 34 through 225, 113 through 261, 113 through 225, 120 through 261, or 120 through 225 of SEQ ID NO:2;

(b) fragments of a polypeptide according to (a) that bind CD40; and

(c) polypeptides encoded by DNA which hybridizes to a DNA that encodes a peptide of (a) or (b), under stringent conditions (hybridization in 6.times. SSC at

63.degree. C. overnight; washing in 3.times. SSC at 55.degree. C.), and which bind to CD40.

4. The method according to claim 3, wherein the soluble, oligomeric CD40 ligand comprises a polypeptide is selected from the group consisting of:

(a) a polypeptide having an amino acid sequence as set forth in SEQ ID NO:2 wherein a cysteine at amino acid 194 is replaced with another amino acid; and

(b) a polypeptide that is a fragment of the polypeptide (a) that binds CD40; wherein the amino acid that is substituted for the cysteine at amino acid 194 is selected from the group consisting of tryptophan, serine, aspartic acid, and lysine.

5. The method according to claim 1, wherein flt-3 ligand is administered to the individual prior to obtaining the dendritic cells, to expand the number of progenitor cells in the circulation of the individual.

6. The method according to claim 5, wherein the dendritic cells are obtained by obtaining hematopoietic stem or progenitor cells from the individual, and contacting the hematopoietic stem or progenitor cells with a molecule selected from the group consisting of flt-3 ligand, GM-CSF, IL-4, TNF-.alpha., IL-3, c-kit ligand, fusions of GM-CSF and IL-3, and combinations thereof.

7. The method according to claim 1, wherein the activated dendritic cells are administered simultaneously, sequentially or separately with a molecule selected from the group consisting of Interleukins 1, 2, 3, 4, 5, 6, 7, 10, 12 and 15; granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor; a fusion protein comprising Interleukin-3 and granulocyte-macrophage colony stimulating factor; Interferon-.gamma.; TNF; TGF-.beta.; flt-3 ligand; soluble CD40 ligand; soluble CD83; and combinations thereof.

8. The method according to claim 5, wherein the CD40 binding protein comprises an oligomer forming peptide and soluble, oligomeric CD40 ligand, wherein the soluble, oligomeric CD40 ligand comprises a polypeptide selected from the group consisting of:

(a) a polypeptide comprising amino acids 1 through 261, 35 through 261, 34 through 225, 113 through 261, 113 through 225, 120 through 261, or 120 through 225 of SEQ ID NO:2;

(b) fragments of a polypeptide according to (a) that bind CD40;

(c) polypeptides encoded by DNA which hybridizes to a DNA that encodes a polypeptide of (a) or (b), under stringent conditions (hybridization in 6.times. SSC at 63.degree. C. overnight; washing in 3.times. SSC at 55.degree. C.), and which bind to CD40;

(d) a polypeptide according to (a) wherein the cysteine at amino acid 194 is replaced with another amino acid selected from the group consisting of tryptophan, serine, aspartic acid, and lysine; and

(e) a fragment of the polypeptide of (d) which binds CD40.

9. The method according to claim 6, wherein the CD40 binding protein comprises an oligomer forming peptide and soluble, oligomeric CD40 ligand, wherein the soluble, oligomeric CD401 ligand comprises a polypeptide selected from the group consisting of:

(a) polypeptide comprising amino acids 1 through 261, 35 through 261, 34 through 225, 113 through 261, 113 through 225, 120 through 261, or 120 through 225 of SEQ ID NO:2;

(b) fragments of a polypeptide according to (a) that bind CD40;

(c) polypeptides encoded by DNA which hybridizes to a DNA that encodes a peptide of (a) or (b), under stringent conditions (hybridization in 6.times. SSC at 63.degree. C. overnight; washing in 3.times. SSC at 55.degree. C.), and which bind to CD40;

(d) a polypeptide according to (a) wherein the cysteine at amino acid 194 is replaced with another amino acid selected from the group consisting of tryptophan, serine, aspartic acid, and lysine; and

(e) a fragment of the polypeptide of (d) which binds CD40.

10. The method according to claim 7, wherein the CD40 binding protein comprises an oligomer forming peptide and soluble, oligomeric CD40 ligand, wherein the soluble, oligomeric CD40 ligand comprises a polypeptide selected from the group consisting of:

(a) a polypeptide comprising amino acids 1 through 261, 35 through 261, 34 through 225, 113 through 261, 113 through 225, 120 through 261, or 120 through 225 of SEQ ID NO:2;

(b) fragments of a polypeptide according to (a) that bind CD40;

(c) polypeptides encoded by DNA which hybridizes to a DNA that encodes a polypeptide of (a) or (b), under stringent conditions (hybridization in 6.times. SSC at 63.degree. C. overnight; washing in 3.times. SSC at 55.degree. C.), and which bind to CD40;

(d) a polypeptide according to (a) wherein the cysteine at amino acid 194 is replaced with another amino acid selected from the group consisting of tryptophan, serine, aspartic acid, and lysine; and

(e) a fragment of the polypeptide of (d) which binds CD40.

11. A method for stimulating an antigen-specific immune response comprising the steps of:

(a) obtaining hematopoietic stem or progenitor cells from an individual;

(b) obtaining dendritic cells by contacting, ex vivo, the cells of step (a) with cytokines suitable for culturing dendritic cells;

(c) exposing the dendritic cells of step (b) with a gene encoding an antigen, so as to obtain antigen-expressing dendritic cells;

(d) exposing the antigen-expressing dendritic cells of step (c) to a protein which binds CD40 and inhibits binding of CD40 to CD40L, so as to obtain activated, antigen-expressing dendritic cells; and

(e) administering an effective amount of the activated antigen-expressing dendritic cells of step (d) to the individual so as to stimulate the antigen-specific immune response in an individual.

12. The method according to claim 11, wherein the binding protein is selected from the group consisting of:

(a) a soluble, oligomeric CD40 ligand comprising amino acids 1-261 of SEQ ID NO:2 and an oligomer-forming peptide;

(b) a soluble, oligomeric CD40 ligand comprising amino acids 35-261 of SEQ ID NO:2 and an oligomer-forming peptide;

(c) a soluble, oligomeric CD40 ligand comprising amino acids 34-225 of SEQ ID NO:2 and an oligomer-forming peptide;

(d) a soluble, oligomeric CD40 ligand comprising amino acids 113-261 of SEQ ID

NO:2 and an oligomer-forming peptide;

(e) a soluble, oligomeric CD40 ligand comprising amino acids 113-225 of SEQ ID NO:2 and an oligomer-forming peptide;

(f) a soluble, oligomeric CD40 ligand comprising amino acids 120-261 of SEQ ID NO:2 and an oligomer-forming peptide;

(g) a soluble, oligomeric CD40 ligand comprising amino acids 120-225 of SEQ ID NO:2 and an oligomer-forming peptide; and

(h) fragments of a polypeptide according to (a)-(g) that bind CD40.

13. The method of claim 12 wherein the oligomer-forming peptide is an immunoglobulin heavy chain encoded by nucleotides 1-740 of SEQ ID NO:3.

14. The method of claim 12 wherein the oligomer-forming peptide is a leucine zipper represented by amino acids 1-33 of SEQ ID NO:4.

15. The method of claim 11 wherein the cysteine at amino acid 194 of SEQ ID NO:2 is substituted with an amino acid selected from the group consisting of tryptophan, serine, aspartic acid and lysine.

WEST

 Generate Collection 

L9: Entry 13 of 14

File: USPT

Nov 2, 1999

US-PAT-NO: 5976546  
DOCUMENT-IDENTIFIER: US 5976546 A

TITLE: Immunostimulatory compositions

DATE-ISSUED: November 2, 1999

## INVENTOR-INFORMATION:

| NAME                 | CITY       | STATE | ZIP CODE | COUNTRY |
|----------------------|------------|-------|----------|---------|
| Laus; Reiner         | San Carlos | CA    |          |         |
| Ruegg; Curtis Landon | San Carlos | CA    |          |         |
| Wu; Hongyu           | Palo Alto  | CA    |          |         |

## ASSIGNEE-INFORMATION:

| NAME                 | CITY    | STATE | ZIP CODE | COUNTRY | TYPE CODE |
|----------------------|---------|-------|----------|---------|-----------|
| Dendreon Corporation | Seattle | WA    |          |         | 02        |

APPL-NO: 09/ 146283 [PALM]  
DATE FILED: September 3, 1998

## PARENT-CASE:

The application is a divisional of U.S. patent application Ser. No. 08/579,823 filed Dec. 28, 1995, now pending.

INT-CL: [06] A61 K 39/00, A61 K 39/385, C07 K 1/00, C07 K 14/00

US-CL-ISSUED: 424/192.1; 424/193.1, 424/194.1, 424/195.11, 530/350, 530/351  
US-CL-CURRENT: 424/192.1; 424/193.1, 424/194.1, 424/195.11, 530/350, 530/351

FIELD-OF-SEARCH: 424/192.1, 424/193.1, 424/194.1, 424/195.11, 530/350, 530/351

## PRIOR-ART-DISCLOSED:

## U. S. PATENT DOCUMENTS

| PAT-NO                                  | ISSUE-DATE | PATENTEE-NAME | US-CL |
|---|------------|---------------|-------|
| <input type="checkbox"/> <u>5616477</u> | April 1997 | Price         |       |

ART-UNIT: 165

PRIMARY-EXAMINER: Caputa; Anthony C.

ASSISTANT-EXAMINER: Navarro; Mark

ATTY-AGENT-FIRM: Judge; Linda R. Dehlinger &amp; Associates

**ABSTRACT:**

Disclosed are therapeutic compositions and methods for inducing cytotoxic T cell responses in vitro and in vivo. The therapeutic compositions consist of antigen presenting cells activated by contact with a polypeptide complex constructed by joining together a dendritic cell-binding protein and a polypeptide antigen. Also disclosed are expression vectors and systems for producing the polypeptide complexes.

2 Claims, 9 Drawing figures

**WEST** [Generate Collection](#) [Print](#)

L9: Entry 13 of 14

File: USPT

Nov 2, 1999

DOCUMENT-IDENTIFIER: US 5976546 A  
TITLE: Immunostimulatory compositions

Brief Summary Text (14):

These limitations are overcome by the discovery encompassed by the present invention. It is the discovery of the present invention that a T-cell response, and specifically, an MHC-Class I mediated T-cell response, can be stimulated by an isolated or soluble protein, when it is presented to the immune system as part of a complex with a dendritic cell binding protein, and more particularly GM-CSF. It is the further discovery of the present invention that such a response can be stimulated *in vitro*. As discussed above, *in vitro* stimulation of such a response has not previously been demonstrated using a full-length soluble antigen. The present invention provides for induction by isolated or soluble proteins of cellular immunity *in vitro* by presenting a specific antigen to an antigen presenting cell (APC), such as a dendritic cell, as part of an immunogenic fusion protein.

Brief Summary Text (15):

An important aspect of the present invention is the choice of fusion partner protein, a dendritic cell binding protein, such as granulocyte-macrophage colony stimulating protein (GM-CSF). Without relying on any particular mechanistic theory, it is believed that the protein antigen is transported over the plasma membrane of the APC in a receptor mediated non-disruptive way. It is further believed that the dendritic cell binding portion of the fusion protein serves to preserve the viability and functionality of the APC.

Detailed Description Text (37):

The use as APC's of dendritic cells stimulated by GM-CSF fusion antigens yields superior results to other approaches such as peptide pulsed dendritic cells. It is known that dendritic cells pulsed with 8-11-mer peptides induce immunity that is directed to a single T-cell epitope. Proteins incorporated into liposomes or delivered by osmotic shock induce reactivity towards multiple T-cell epitopes; however, this process is relatively ineffective due to the inherent toxicity of these treatments to dendritic cells. GM-CSF fusion antigens of the present invention, on the other hand, induce immunity towards multiple epitopes and preserve and enhance at the same time viability and function of the dendritic cell.

Detailed Description Text (39):

In experiments carried out in support of the present invention, the fusion protein consisting of PAP and GM-CSF described in the previous section was used for *in vitro* introduction to dendritic cells and subsequent activation of cytolytic T cells, as detailed in Example 4. Briefly, HLA-A2.1 positive PBMNC were isolated by standard methods and primed with the fusion protein for 2-5 days. The cell mixture was depleted of CD4.sup.+ T-cells, separated into high and low density fractions, and the separate cultures were restimulated weekly with autologous PAP GM-CSF pulsed APC's. Lytic potential of the T-cells present in the fractions was assessed using a standard chromium release assay using an HLA-A2.1-transgenic prostate carcinoma cell line as target. This novel cell line was constructed according to the methods detailed in Example 3 herein and is useful in screening and analysis of HLA class I restricted cytotoxic T-lymphocytes.

Detailed Description Text (46):

In practice, dendritic cells are isolated from an individual, using known methods, or preferably, as described in Example 5. The dendritic cells (or other APC's) are mixed

with 10 ng/ml equivalent of GM-CSF fusion antigen, as described in Example 4. The cell preparation may then be depleted of CD4.sup.+ T-cells by solid phase immunoadsorption and further fractionated to enrich for cells having cytolytic activity. Doses of about 10.sup.7 cells are then administered to the subject by intravenous or central injection according to established procedures (e.g., infusion over 30 to 60 minutes). The responsiveness of the subject to this treatment is measured by monitoring the induction of a cytolytic T-cell response, a helper T-cell response and antibody response towards the antigen in peripheral blood mononuclear cells by methods well known in the art.

WEST

 Generate Collection 

L5: Entry 10 of 17

File: USPT

Apr 3, 2001

US-PAT-NO: 6210662  
 DOCUMENT-IDENTIFIER: US 6210662 B1

TITLE: Immunostimulatory composition

DATE-ISSUED: April 3, 2001

102e ref

## INVENTOR-INFORMATION:

| NAME                 | CITY       | STATE | ZIP CODE | COUNTRY |
|----------------------|------------|-------|----------|---------|
| Laus; Reiner         | San Carlos | CA    |          |         |
| Ruegg; Curtis Landon | San Carlos | CA    |          |         |
| Wu; Hongyu           | Palo Alto  | CA    |          |         |

## ASSIGNEE-INFORMATION:

| NAME                 | CITY    | STATE | ZIP CODE | COUNTRY | TYPE CODE |
|----------------------|---------|-------|----------|---------|-----------|
| Dendreon Corporation | Seattle | WA    |          |         | 02        |

APPL-NO: 09/ 344195 [PALM]

DATE FILED: June 24, 1999

## PARENT-CASE:

This application is a continuation of U.S. patent application Ser. No. 09/146,283, filed Sep. 3, 1998, now granted as U.S. Pat. No. 5,976,546, which is a divisional of U.S. patent application Ser. No. 08/579,823, filed Dec. 28, 1995 now granted as U.S. Pat. No. 6,080,409, both of which are herein incorporated by reference.

INT-CL: [07] A01 N 63/00, A01 N 65/00, C12 N 5/00, C12 N 5/08

US-CL-ISSUED: 424/93.1; 435/325, 435/366, 435/372, 435/372.3

US-CL-CURRENT: 424/93.1; 435/325, 435/366, 435/372, 435/372.3

FIELD-OF-SEARCH: 424/93.1, 435/325, 435/366, 435/372, 435/372.3

## PRIOR-ART-DISCLOSED:

## U.S. PATENT DOCUMENTS

| PAT-NO         | ISSUE-DATE   | PATENTEE-NAME     | US-CL |
|----------------|--------------|-------------------|-------|
| <u>4861589</u> | August 1989  | Ju                |       |
| <u>5019384</u> | May 1991     | Gefter et al.     |       |
| <u>5078996</u> | January 1992 | Colon, III et al. |       |
| <u>5194254</u> | March 1993   | Barber et al.     |       |
| <u>5616477</u> | April 1997   | Price             |       |
| <u>5677171</u> | October 1997 | Hudziak et al.    |       |

## FOREIGN PATENT DOCUMENTS

| FOREIGN-PAT-NO | PUBN-DATE      | COUNTRY | US-CL |
|----------------|----------------|---------|-------|
| 0 406 857 A1   | January 1991   | EP      |       |
| WO 91/13632    | September 1991 | WO      |       |
| WO 93/20185    | October 1993   | WO      |       |
| WO 94/17192    | August 1994    | WO      |       |
| WO 94/21287    | September 1994 | WO      |       |
| WO 95/21862    | August 1995    | WO      |       |
| WO 95/23814    | September 1995 | WO      |       |
| WO 95/34638    | December 1995  | WO      |       |

## OTHER PUBLICATIONS

- Berzofsky, J.A., and Berkower, I.J., "Immunogenicity and Antigen Structure," in Fundamental Immunology, Third Edition (Paul, W.E., Ed.) Raven Press, Ltd., New York, NY, pp. 235-274 (1993).
- Disis, M.L., et al., "Peptide-Based, but Not Whole Protein, Vaccines Elicit Immunity to HER-2/neu, an Oncogenic Self-Protein," *J. Immunol.* 156:3151-3158 (1996).
- Fisk, B., et al., "Identification of Immunodominant Peptide of HER-2/neu Protooncogene Recognized by Ovarian Tumor-Specific Cytotoxic T Lymphocyte Lines," *J. Exp. Med.* 181:2109-2117 (1995).
- Flamand, V., et al., "Murine Dendritic Cells in Vitro with Tumor Antigen Induce Tumor Resistance in Vivo," *Eur. J. Immunol.* 24:605-610 (1994).
- Lin, R. -H., et al., "Induction of Autoreactive B Cells Allows Priming of Autoreactive T Cells," *J. Exp. Med.* 173:1433-1439 (1991).
- Mamula, M.J., et al., "Breaking T Cell Tolerance with Foreign and Self Co-Immunogens," *J. Immunol.* 149 (3) : 789-795 (1992).
- Schirrmbeck, R., et al., "Immunization of Mice with the N-Terminal (1-272) Fragment of Simian Virus 40 Large T Antigen (Without Adjuvants) Specifically Primes Cytotoxic T Lymphocytes," *Eur. J. Immunol.* 23:1528-1534 (1993).
- Schwartz, R.H., "Immunological Tolerance," in Fundamental Immunology, Third Edition (Paul, W.E., Ed.) Raven Press, Ltd., New York, NY, pp. 677-720 (1993).
- Tao, M.-H., and Levy, R., "Idiotype/Granulocyte-Macrophage Colony-Stimulating Factor Fusion Protein as a Vaccine for B-Cell Lymphoma," *Nature* 362:755 (1993).
- Sharief, F.S., et al., "Human Prostatic Acid Phosphatase:cDNA Cloning, Gene Mapping and Protein Sequence Homology with Lysosomal Acid Phosphatase," *Biochemical and Biophysical Research Communications*, 160(1) : 79-86 (1989).
- Stauss H.J., et al., "Induction of Cytotoxic T Lymphocytes with Peptides in vitro: Identification of Candidate T-cell Epitopes in Human Papilloma Virus," *Proc. Natl. Acad. Sci. USA*, 89:7871-7875 (1992).
- Takahashi, H., et al., "Induction of CD8.sup.+ Cytotoxic T Cells by Immunization with Purified HIV-1 Envelope Protein in ISCOMs," *Nature*, 344:873-875 (1990).

ART-UNIT: 165

PRIMARY-EXAMINER: Navarro; Albert

ATTY-AGENT-FIRM: Judge; Linda R. Iota Pi Law Group

## ABSTRACT:

Disclosed are therapeutic compositions and methods for inducing cytotoxic T cell responses in vitro and in vivo. The therapeutic compositions consist of antigen presenting cells activated by contact with a polypeptide complex constructed by joining together a dendritic cell-binding protein and a polypeptide antigen. Also disclosed are expression vectors and systems for producing the polypeptide complexes.

3 Claims, 9 Drawing figures

**WEST** [Generate Collection](#) [Print](#)

L5: Entry 10 of 17

File: USPT

Apr 3, 2001

DOCUMENT-IDENTIFIER: US 6210662 B1  
TITLE: Immunostimulatory composition

Brief Summary Text (23) :

In further related aspects, the invention also includes expression vectors and expression systems for producing the above-described immunostimulatory fusion proteins, as well as substantially purified nucleic acid molecules that encode such fusion proteins. In preferred embodiments, the nucleic acid molecules code for fusion proteins consisting essentially of GM-CSF and prostatic acid phosphatase or of GM-CSF and Her2.

Drawing Description Text (9) :

FIG. 8 shows the nucleic acid (SEQ ID NO: 3) and amino acid (SEQ ID NO: 4) sequences of a GM-CSF-Her2 fusion protein in accordance with the present invention.

Detailed Description Text (32) :

Fusion proteins constructed to incorporate oncogene product antigens are exemplified by incorporation of the oncogene product Her2. Her2 is a growth factor receptor belonging to the EGF-R family of receptors. It is overexpressed by breast cancer cells, ovarian cancer cells and a variety of other cancer cells. The cDNA coding for the extracellular domain of Her2 is cloned from a breast cancer cell line and fused to the GM-CSF cDNA, essentially as detailed for PAP-GM-CSF, above.

Detailed Description Text (33) :

Production of the soluble protein can be verified using Her2-specific monoclonal antibodies in an ELISA test, according to methods well-known in the art. The fusion protein includes the sequences for the extracellular domain (amino acids 1-652) of Her2 (GenBank) and GM-CSF (FIG. 8). In this particular fusion protein the two proteins are linked by a leucine/glutamic acid linker which is generated by inserting a XhoI site. Other oncogene product antigens are similarly incorporated into fusion proteins according to the methods described herein, using published sequences. In addition, other antigens, such as viral antigens, may be part of a fusion construct, according to the methods described herein.

**WEST**  NPA  
FD 10/18/00

L8: Entry 7 of 11

File: USPT

Apr 8, 2003

DOCUMENT-IDENTIFIER: US 6544518 B1

TITLE: Vaccines

Brief Summary Text (97) :

The HER-2/neu PD is 268 amino acids in length, is intracellular, and can be phosphorylated by protein tyrosine kinases. The region shares no identity with the corresponding part of other tyrosine kinase receptors. Thus, the specificity and uniqueness of this domain makes it particularly preferred for use as a tumour vaccine. However, the expression of this domain alone in bacterial and mammalian cells is problematic. For example, the resultant PD protein is very labile and is not appropriate for large scale production. In one embodiment, this invention thus preferably utilises a fusion comprising all or part of the intracellular domain or the phosphorylation domain to all or part of the HER-2/neu extracellular domain. The ECD-ICD fusion proteins and the ECD-PD fusion proteins of the invention are soluble. are secreted and are stable in culture media.

Brief Summary Text (98) :

The vaccines of the invention will be useful against any cancer characterised by tumour associated antigen expresion, such as HER-2/neu expression. In addition to allowing increased expression of the intracellular domain or phosphorylation domain, or variants thereof, as a fusion protein with the extracelluar domain or its variants, the ECD-ICD and ECD-PD fusion proteins provide for an improved vaccine formulation.

**WEST** [Generate Collection](#) [Print](#)

L22: Entry 21 of 29

File: USPT

Apr 8, 2003

DOCUMENT-IDENTIFIER: US 6544518 B1  
TITLE: Vaccines

Brief Summary Text (91):

The Her2-neu antigen may be the entire Her2-neu antigen or portions thereof. Preferred portions comprises the extracellular domain. In a more preferred embodiment there is provided an fusion protein comprising an extracellular domain linked to a portion of the intracellular domain as disclosed in WO 00/44899.

Brief Summary Text (94):

The "HER-2/neu ECD-ICD fusion protein," also referred to herein as "ECD-ICD" or "ECD-ICD fusion protein," refers to a fusion protein (or fragments thereof) comprising the extracellular domain (or fragments thereof) and the intracellular domain (or fragments thereof) of the HER-2/neu protein. These represent preferred antigens to utilise in the context of the present invention. As used herein, the ECD-ICD fusion protein does not include a substantial portion of the HER-2/neu transmembrane domain, and preferably does not include any of the HER-2/neu transmembrane domain.

Brief Summary Text (95):

The "HER-2/neu ECD-PD fusion protein,>also referred to as "ECD-PD" or "ECD-PD fusion protein," or the "HER-2/neu ECD-.DELTA.PD fusion protein," also referred to as "ECD-.DELTA.PD" or ECD-.DELTA.PD fusion protein," refer to fusion proteins (or fragments thereof) comprising the extracellular domain (or fragments thereof) and phosphorylation domain (or fragments thereof, eg, .DELTA.PD) of the HER-2/neu protein. The ECD-PD and ECD-.DELTA.PD fusion proteins do not include a substantial portion of the HER-2/neu transmembrane domain, and preferably do not include any of the HER-2/neu transmembrane domain.

Brief Summary Text (97):

The HER-2/neu PD is 268 amino acids in length, is intracellular, and can be phosphorylated by protein tyrosine kinases. The region shares no identity with the corresponding part of other tyrosine kinase receptors. Thus, the specificity and uniqueness of this domain makes it particularly preferred for use as a tumour vaccine. However, the expression of this domain alone in bacterial and mammalian cells is problematic. For example, the resultant PD protein is very labile and is not appropriate for large scale production. In one embodiment, this invention thus preferably utilises a fusion comprising all or part of the intracellular domain or the phosphorylation domain to all or part of the HER-2/neu extracellular domain. The ECD-ICD fusion proteins and the ECD-PD fusion proteins of the invention are soluble. are secreted and are stable in culture media.

Brief Summary Text (98):

The vaccines of the invention will be useful against any cancer characterised by tumour associated antigen expression, such as HER-2/neu expression. In addition to allowing increased expression of the intracellular domain or phosphorylation domain, or variants thereof, as a fusion protein with the extracellular domain or its variants, the ECD-ICD and ECD-PD fusion proteins provide for an improved vaccine formulation.

**WEST****End of Result Set** Generate Collection      Print

NPA

L1: Entry 12 of 12

File: USPT

Jun 18, 2002

FD 8/21/00

DOCUMENT-IDENTIFIER: US 6406681 B1  
TITLE: Method of treating a systemic diseaseDetailed Description Text (22):

The term "vaccines" refers to therapeutic compositions for stimulating humoral and cellular immune responses, either isolated, or through an antigen presenting cell, such as an activated dendritic cell, that is able to activate T-cells to produce a multivalent cellular immune response against a selected antigen. The potent antigen presenting cell is stimulated by exposing the cell *in vitro* to a polypeptide complex. The polypeptide complex may comprise a dendritic cell-binding protein and a polypeptide antigen, but preferably, the polypeptide antigen is either a tissue-specific tumor antigen or an oncogene gene product. However, it is appreciated that other antigens, such as viral antigens can be used in such combination to produce immunostimulatory responses. In another preferred embodiment, the dendritic cell-binding protein that forms part of the immunostimulatory polypeptide complex is GM-CSF. In a further preferred embodiment, the polypeptide antigen that forms part of the complex is the tumor-specific antigen prostatic acid phosphatase. In still other preferred embodiments, the polypeptide antigen may be any one of the oncogene product peptide antigens. The polypeptide complex may also contain, between the dendritic cell-binding protein and the polypeptide antigen, a linker peptide. The polypeptide complex may comprise a dendritic cell-binding protein covalently linked to a polypeptide antigen, such polypeptide complex being preferably formed from a dendritic cell binding protein, preferably GM-CSF, and a polypeptide antigen. The polypeptide antigen is preferably a tissue-specific tumor antigen such as prostatic acid phosphatase (PAP), or an oncogene product, such as Her2, p21RAS, and p53; however, other embodiments, such as viral antigens, are also within the scope of the invention.

**WEST** [Generate Collection](#) [Print](#)

L30: Entry 4 of 10

File: USPT

Jun 13, 2000

US-PAT-NO: 6075122

DOCUMENT-IDENTIFIER: US 6075122 A

TITLE: Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated

DATE-ISSUED: June 13, 2000

## INVENTOR-INFORMATION:

| NAME               | CITY          | STATE | ZIP CODE | COUNTRY |
|--------------------|---------------|-------|----------|---------|
| Cheever; Martin A. | Mercer Island | WA    |          |         |
| Disis; Mary L.     | Renton        | WA    |          |         |

## ASSIGNEE-INFORMATION:

| NAME                     | CITY    | STATE | ZIP CODE | COUNTRY | TYPE CODE |
|--------------------------|---------|-------|----------|---------|-----------|
| University of Washington | Seattle | WA    |          |         | 02        |

APPL-NO: 08/ 466680 [PALM]

DATE FILED: June 6, 1995

## PARENT-CASE:

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a continuation of U.S. patent application Ser. No. 08/414,417, filed Mar. 31, 1995, U.S. Pat. No. 5,801,005; which application is a continuation-in-part application to Ser. No. 08/106,112, filed Aug. 12, 1993, abandoned; which application is a continuation-in-part application to Ser. No. 08/033,644, filed Mar. 17, 1993, abandoned.

INT-CL: [07] C07 K 14/47, C07 K 14/705

US-CL-ISSUED: 530/350; 530/806, 530/828

US-CL-CURRENT: 530/350; 530/806, 530/828

FIELD-OF-SEARCH: 530/300, 530/327, 530/328, 530/350, 530/806, 530/828, 530/326

## PRIOR-ART-DISCLOSED:

## U.S. PATENT DOCUMENTS

| PAT-NO                                  | ISSUE-DATE    | PATENTEE-NAME     | US-CL |
|---|---------------|-------------------|-------|
| <input type="checkbox"/> <u>3766162</u> | October 1973  | Spector           |       |
| <input type="checkbox"/> <u>3791932</u> | February 1974 | Schuurs et al.    |       |
| <input type="checkbox"/> <u>3817837</u> | June 1974     | Rubenstein et al. |       |
| <input type="checkbox"/> <u>3850752</u> | November 1974 | Schuurs et al.    |       |
| <input type="checkbox"/> <u>3901654</u> | August 1975   | Gross             |       |
| <input type="checkbox"/> <u>3935074</u> | January 1976  | Rubenstein et al. |       |
| <input type="checkbox"/> <u>3984533</u> | October 1976  | Uzgiris           |       |
| <input type="checkbox"/> <u>3996345</u> | December 1976 | Ullman et al.     |       |
| <input type="checkbox"/> <u>4034074</u> | July 1977     | Miles             |       |
| <input type="checkbox"/> <u>4098876</u> | July 1978     | Piasio et al.     |       |
| <input type="checkbox"/> <u>4233402</u> | November 1980 | Maggio et al.     |       |
| <input type="checkbox"/> <u>4452901</u> | June 1984     | Gordon et al.     |       |
| <input type="checkbox"/> <u>5320947</u> | June 1994     | Cheever et al.    |       |

## FOREIGN PATENT DOCUMENTS

| FOREIGN-PAT-NO | PUBN-DATE     | COUNTRY | US-CL |
|----------------|---------------|---------|-------|
| WO 90/14357    | November 1990 | WO      |       |
| WO 91/02062    | February 1991 | WO      |       |

## OTHER PUBLICATIONS

- Fisk et al., "Oligopeptide Induction of a Cytotoxic T Lymphocyte Response to HER-2/Neu Proto-oncogene in Vitro," *Cellular Immunology* 157: 415-427, 1994.
- Ioannides et al., "Cytotoxic T-Cell Clones Isolated from Ovarian Tumour Infiltrating Lymphocytes Recognize Common Determinants on Non-Ovarian Tumour Clones," *Scand. J. Immunol.* 37: 413-424, 1993.
- Alper et al., "The Presence of c-erbB-2 Gene Product-related Protein in Culture Medium Conditioned by Breast Cancer Cell Line SK-BR-3," *Cell Growth & Differentiation* 1: 591-599, 1990.
- Bargmann et al., "The neu oncogene encodes an epidermal growth factor receptor-related protein," *Nature* 319: 226-230, 1986.
- Bishop and Orosz, "Limiting Dilution Analysis For Alloreactive, TCGF-Secretory T Cells. Two Related LDA Methods That Discriminate Between Unstimulated Precursor T Cells and In Vivo-Alloactivated T Cells," *Transplantation* 47(4): 671-677, 1989.
- Bowen-Pope et al., "Production of platelet-derived growth factor-like molecules and reduced expression of platelet-derived growth factor receptors accompany transformation by a wide spectrum of agents," *Proc. Natl. Acad. Sci. USA* 81: 2396-2400, 1984.
- Brooks et al., "Human lymphocyte markers defined by antibodies derived from somatic cell hybrids," *Clin. exp. Immunol.* 39: 477-485, 1980.
- Brown et al., "Protein Antigens of Normal and Malignant Human Cells Identified by Immunoprecipitation with Monoclonal Antibodies," *Journal of Biological Chemistry* 255(11): 4980-4983, 1980.
- Burnette et al., "'Western Blotting': Electrophoretic Transfer of Proteins from Sodium Dodecyl Sulfate-Polyacrylamide Gels to Unmodified Nitrocellulose and Radiographic Detection with Antibody and Radioiodinated Protein A," *Analytical Biochemistry* 112: 195-203, 1981.
- Dhut et al., "BCR-ABL and BCR Proteins: Biochemical Characterization and Localization," *Leukemia* 4(11): 745-750, 1990.
- Falk et al., "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules," *Nature* 351: 290-296, 1991.
- Feller and de la Cruz, "Identifying antigenic T-cell sites," *Nature* 349: 720-721, 1991.
- Iglehart et al., "Increased erbB-2 Gene Copies and Expression in Multiple Stages of

Breast Cancer," *Cancer Research* 50: 6701-6707, 1990.

Ioannides et al., "T-Cell Recognition of Oncogene Products: A New Strategy for Immunotherapy," *Molecular Carcinogenesis* 6: 77-82, 1992.

Kallioniemi et al., "ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization," *Proc. Natl. Acad. Sci.* 89: 5321-5325, 1992.

Kerns et al., "c-erbB-2 Expression In Breast Cancer Detected by Immunoblotting and Immunohistochemistry," *Journal of Histochemistry and Cytochemistry* 38(12): 1823-1830, 1990.

Laemmli, U., "Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4," *Nature* 227: 680-685, 1970.

Leitzel et al., "Elevated Soluble c-erbB2 Antigen Levels in the Serum and Effusions of a Proportion of Breast Cancer Patients," *Journal of Clinical Oncology* 10(9): 1436-1443, 1992.

Lippman, M., "Potential Contributions of Breast Cancer Biology to Management of Breast Cancer," *Advances in Oncology* 8(3): 26-28, 1992.

Maguire and Greene, "The neu (c-erbB-2) Oncogene," *Seminars in Oncology* 16(2): 148-155, 1989.

Margalit et al., "Prediction Of Immunodominant Helper T Cell Antigenic Sites From The Primary Sequence," *Journal of Immunology* 138(7): 2213-2229, 1987.

McKenzie et al., "Induction of Antitumor Immunity by Immunization with a Vaccinia Virus Vector Expressing and Oncogene-encoded Product," in *Vaccines* 88, Cold Spring Harbor Laboratory, 1988, pp. 19-23.

Mietzner et al., "Purification and Characterization of the Major Iron-Regulated Protein Expressed By Pathogenic Neisseriae," *Journal of Experimental Medicine* 165: 1041-1057, 1987.

Mori et al., "In vitro and in vivo Release of Soluble erbB-2 Protein from Human Carcinoma Cells," *Japanese Journal of Cancer Research* 81: 489-494, 1990.

Paik et al., "Pathologic Findings From the National Surgical Adjuvant Breast and Bowel Project: Prognostic Significance of erbB-2 Protein Overexpression in Primary Breast Cancer," *Journal of Clinical Oncology* 8(1): 103-112, 1990.

Parker et al., "Sequence Motifs Important For Peptide Binding To The Human MHC Class I Molecule, HLA-A2," *Journal of Immunology* 149(11): 3580-3587, 1992.

Press et al., "Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues," *Oncogene* 5: 953-962, 1990.

Raines and Ross, "Platelet-derived Growth Factor. I. High Yields Purification and Evidence for Multiple Forms," *Journal of Biological Chemistry* 257(9): 5154-5159, 1982.

Riberdy and Cresswell, "The Antigen-Processing Mutant T2 Suggests a Role for MHC-Linked Genes in Class II Antigen Presentation," *Journal of Immunology* 148(8): 2586-2590, 1992.

Rothbard and Taylor, "A sequence pattern common to T cell epitopes," *EMBO Journal* 7(1): 93-100, 1988.

Spies et al., "A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway," *Nature* 348: 744-747, 1990.

Stern et al., "Oncogenic Activation of p185.sup.neu Stimulates Tyrosine Phosphorylation In Vivo," *Molecular and Cellular Biology* 8(9): 3969-3973, 1988.

Trowsdale et al., "Sequence enclosed in the class II region of the MHC related to the 'ABC' superfamily of transporters," *Nature* 348: 741-744, 1990.

Wide, L., "Solid Phase Antigen-Antibody Systems," in *Radioimmunoassay Methods*, Kirkham and Hunter (eds.), 1973, pp. 405-412.

Zabrecky et al., "The Extracellular Domain of p185/neu Is Released from the Surface of Human Breast Carcinoma Cells, SK-BR-3," *Journal of Biological Chemistry* 266(3): 1716-1720, 1991.

Ioannides, C.G., et al., "CTL Clones Isolated From Ovarian Tumor Infiltrating Lymphocytes Can Recognize Peptides With Sequences Corresponding the the HER2/neu Gene Product," *FASEB J* 6:A1404, 1992.

Ioannides, C.G., et al., "Antigens Recognized by T Cells in Ovarian Cancer," Abstracts of the Fourth International Conference of Anticancer Research, 1992, p. 1870.

Ioannides, C.G., "Antigens and Vaccines of Female Genital Cancers," Society for Biological Therapy 1992 Annual Meeting, 1992, p. 27.

Ioannides, C.G., et al., "Cytotoxic T Cells Isolated From Ovarian Malignant Ascites Recognize a Peptide Derived From the HER-2/neu Proto-oncogene," *Cell Immunol.* 151:225-234, 1993.

Disis, M.L., et al., "Existent T-Cell and Antibody Immunity to HER-2/neu Protein in

"Patients With Breast Cancer," Cancer Res. 54:16-20, 1994.  
Coussens, Science 230: 1132-1139, 1985.  
McGlynn Eur. J. Biochem 207: 265-275, 1992.  
Semba, PNAS 82:6497-6501, 1985.  
Flanagan & Leder, PNAS 85: 8057-8061, 1988.  
Yamamoto, Nature 319: 230-233, 1986.  
Bodmer Human Immunology 30: 259-261, 1991.

ART-UNIT: 162

PRIMARY-EXAMINER: Johnson; Nancy A.

ATTY-AGENT-FIRM: Seed and Berry LLP

ABSTRACT:

Methods for the detection, monitoring and treatment of malignancies in which the HER-2/neu oncogene is associated are disclosed. Detection of specific T cell activation (e.g., by measuring the proliferation of T cells) in response to in vitro exposure to the HER-2/neu protein, or detection of immunocomplexes formed between the HER-2/neu protein and antibodies in body fluid, allows the diagnosis of the presence of a malignancy in which the HER-2/neu oncogene is associated. The present invention also discloses methods and compositions, including peptides, for treating such malignancies.

2 Claims, 24 Drawing figures

## WEST

 Generate Collection 

L30: Entry 4 of 10

File: USPT

Jun 13, 2000

DOCUMENT-IDENTIFIER: US 6075122 A

TITLE: Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated

FD = 6/6/95

INVENTOR (1):  
Cheever; Martin A.

Drawing Description Text (8):

FIG. 7 pictorially illustrates that some breast cancer patients have antibodies directed to both the extracellular and intracellular domain of the HER-2/neu protein. Sera of breast cancer patients is tested against the extracellular domain ("ECD protein") or the intracellular domain ("ICD protein"), in lanes A and B, respectively.

Detailed Description Text (39):

Peptides, each 15 amino acids in length, that encompass both the AMPHI and Rothbard motifs were constructed. The optimal peptide length for class II MHC binding depends upon the particular MHC molecule and may be shorter than 15 amino acids. However, class II MHC responses to exogenous peptides allow for endocytosis and intracellular processing of longer peptides. One of the synthetic peptides (p42-56), HLDMLRHLYQGCQVV (Seq. ID No. 30), is located in the extracellular domain and has 33% homology to epidermal growth factor receptor (EGFR). Two other synthetic peptides, SRLLGICLTSTVQLV (p783-797) (Seq. ID No. 45) and TLERPKTLSPGKNGV (p1166-1180) (Seq. ID No. 54) are both located in the intracellular domain and have 87% and 7% homology to EGFR respectively. The peptides as well as partially purified whole protein (p185.sup.HER-2/neu) were used in subsequent defined experiments to detect CD4+ T cell proliferation responses (Section C below).

Detailed Description Text (60):

According to the current motif, the p185.sup.HER-2/neu protein contains a substantial number of peptides with amino acid sequences possibly appropriate for binding to the class I MHC antigen HLA-A2.1. Evaluation of the 1255 aa structure of p185.sup.HER-2/neu revealed at least 19 peptide segments of 9 aa in length that contained at least one of the dominant anchor residues. Of note, the current HLA-A2.1 motif places 6 amino acids between the dominant anchor amino acids at residues 2 and 9. Recent studies show that alterations in secondary structure of peptides can sometimes allow for additional intervening residues, and thus longer binding peptides. In the present experiment, 9-mer peptides were evaluated. The 10 peptides with both dominant residues were considered. The arbitrary scoring system awarded +3 for a dominant anchor residue, +2 for a strong binding residue, and +1 for a weak binding residue. Emphasis was placed on presence or absence of dominant anchor residues as they appear to be of prime importance for peptide binding to HLA-A2 (Parker et al., J. Immunol. 148:3580-3587, 1992). Four peptides were synthesized (Table 3). One is located in the extracellular domain of the protein and three are located in the intracellular domain. Homology to EGFR ranges from 11% to 89% (Bargmann et al., Nature 319:226-230, 1986).

Check  
① config  
② cancer?  
③ fusion?  
④ to  
of kinase?  
GM-CSF?

Detailed Description Text (67):

Initial experiments examined response to p48-56 which is normally present in the extracellular domain and p789-797 which is normally present in the intracellular domain, both of which were found to bind to HLA-A2.1. Four of four peptides with a motif theoretically appropriate for binding to HLA-A2.1 are shown to actually bind to HLA-A2.1 in a class I MHC molecule stabilization assay (Table 4). T2 cells were

incubated for 18 hours with the depicted synthetic p185.sup.HER-2/neu peptides. Cells were then washed and stained with antihuman HLA-A2 antibody (3%), a second step FITC-conjugated antibody (3%) was then added. The % increase of class I on cell surface as measured by increased fluorescent intensity of cells incubated with peptide compared to cells incubated in medium alone is indicated.

Detailed Description Text (76) :

Recombinant proteins of the extracellular and intracellular domain portions of HER-2/neu were obtained. The extracellular protein (110kD) and intracellular protein (75 kD) were resolved on a 7.5%; SDS-PAGE gel and incubated with patient sera as primary antibody as previously described. The sera identified both proteins proving that some patients have antibodies directed to both the extracellular and intracellular domain of the HER-2/neu protein (FIG. 7).

Detailed Description Text (90) :

One group of rats was immunized with a mixture of extracellular domain (ECD) peptides and one group with a mixture of intracellular domain (ICD) peptides. The 15 final group received adjuvant alone. Peptides were administered at a final concentration of 100 .mu.g each in a total volume of 200 .mu.l. The animals underwent 3 immunizations each 14-16 days apart with either CFA or IFA as adjuvant (Sigma ImmunoChemicals, St. Louis, Mo.). 16 days after the third immunization sera was obtained for assessment of immune response.

Detailed Description Paragraph Table (6) :

TABLE 3

| p185.sup.HER-2/neu Peptides Constructed for Binding in HLA-A2.1 Motif |   |   |   |   |   |   |   |   |   |       |
|---|---|---|---|---|---|---|---|---|---|-------|
| p185.sup.HER-2/neu Amino Acid Position                                | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | Score |
| Location to EGFR  |   |   |   |   |   |   |   |   |   |       |

p48-56.sup.HER-2/neu H L Y Q G C Q V V 8\* Extracellular 33% (Seq. ID No. 1)

p789-797.sup.HER-2/neu C L T S T V Q L V 9\* Intracellular 89% (Seq. ID No. 7)

p851-859.sup.HER-2/neu V L V K S P N H V 9\* Intracellular 78% (Seq. ID No. 9)

p1172-1180.sup.HER-2/neu T L S P G K N G V 9\* Intracellular 11% (Seq. ID No. 10)

\*Peptide

contains both dominant anchor residues

Detailed Description Paragraph Table (8) :

TABLE 5 Peptides from the Rat neu Protein for Immunization Homology Rat Protein to Human Sequence Amino Acids Domain neu

|            |                    |     |      |                  |
|------------|--------------------|-----|------|------------------|
| p45-59     | HLDMLRHLYQGCQVV    | ECD | 100% | (Seq. ID No. 30) |
| p98-112    | PLQRLRIVRGTLFE     | ECD | 100% | (Seq. ID No. 31) |
| p323-337   | NQEVTAEDEGTQRCEK   | ECD | 100% | (Seq. ID No. 56) |
| p332-349   | TQRCEKCSKPCARVCYGL | ECD | 100% | (Seq. ID No. 60) |
| p433-447   | RIIRGRILHDGAYSL    | ECD | 80%  | (Seq. ID No. 67) |
| p781-795   | GVGSPYVSRLLGICL    | ICD | 100% | (Seq. ID No. 44) |
| p788-802   | SRLLGICLTSTVQLV    | ICD | 100% | (Seq. ID No. 45) |
| p932-946   | PAREIPDLLEKGERL    | ICD | 100% | (Seq. ID No. 49) |
| p1171-1185 | TLERPKTLSPGKNGV    | ICD | 100% | (Seq. ID No. 54) |

ECD = extracellular domain ICD = intracellular domain

**WEST** [Generate Collection](#) [Print](#)

L23: Entry 34 of 43

File: USPT

Dec 25, 2001

DOCUMENT-IDENTIFIER: US 6333169 B1

\*\* See image for Certificate of Correction \*\*

TITLE: HER2 extracellular domain

Abstract Text (1):

An extracellular portion of the HER2 molecule, essentially free of transmembrane and cytoplasmic portions, which is antigenic in animals. Isolated DNA encoding the extracellular portion; an expression vector containing the isolated DNA; and a cell containing the expression vector. A process for producing the extracellular domain. A vaccine containing the extracellular domain.

Brief Summary Text (18):

In a yet further embodiment, the present invention extends to a vaccine comprising the extracellular portion of the HER2 molecule, which may be combined with suitable adjuvants.

Detailed Description Text (40):

In addition to Active Specific Immunotherapy, it should be possible to use the purified extracellular domain to isolate and characterize the putative ligand. The HER2 ligand may be used in turn to deliver toxin to tumor cells which are overexpressing HER2, such as by molecular fusion of the ligand with toxin, or by chemical cross-linking. Alternatively, patients overexpressing HER2 may be vaccinated with HER2 ligand conjugated to, or in combination with, a suitable adjuvant.

Other Reference Publication (22):

Fendly et al., "Successful Immunization of Rhesus Monkeys with Extracellular Domain of p185.sup.HER2 :A Potential Approach to Human Breast Cancer" Vaccine Research 2 (3) :129-139 (1993).

Other Reference Publication (58):

Ezzell, C., "Cancer `Vaccines`: An Idea Whose Time Has Come?" Journal of NIH Research 7:46-49 (Jan. 1995).

## CLAIMS:

4. A method for making a polypeptide fusion comprising an extracellular domain of the HER2 receptor conjugated to a Fc portion of an immunoglobulin molecule, comprising:

(a) culturing a host cell comprising DNA encoding said polypeptide fusion under conditions suitable for expression of said DNA; and

(b) recovering said polypeptide fusion from said host cell.

8. A method for making a vaccine useful for Active Specific Immunotherapy, comprising:

(a) culturing a host cell comprising DNA encoding the extracellular domain of the HER2 receptor or a portion thereof which provokes a humoral and cell-mediated response against HER2 receptor in a patient vaccinated therewith under conditions suitable for expression of said DNA;

(b) recovering said extracellular domain or portion thereof from said host cell; and

(c) combining said recovered extracellular domain or portion thereof with an adjuvant which is safe and effective in humans so as to generate a vaccine which provokes a humoral and cell-mediated response against HER2 receptor in a patient vaccinated therewith.

**WEST****End of Result Set** [Generate Collection](#) 

L21: Entry 3 of 3


File: USPT

Dec 25, 2001

DOCUMENT-IDENTIFIER: US 6333169 B1  
\*\* See image for Certificate of Correction \*\*  
TITLE: HER2 extracellular domain

**CLAIMS:**

4. A method for making a polypeptide fusion comprising an extracellular domain of the HER2 receptor conjugated to a Fc portion of an immunoglobulin molecule, comprising:
- (a) culturing a host cell comprising DNA encoding said polypeptide fusion under conditions suitable for expression of said DNA; and
  - (b) recovering said polypeptide fusion from said host cell.



|               |                          |         |               |           |           |          |       |       |
|---------------|--------------------------|---------|---------------|-----------|-----------|----------|-------|-------|
| PubMed        | Nucleotide               | Protein | Genome        | Structure | PMC       | Taxonomy | OMIM  | Books |
| Search PubMed | <input type="text"/> for |         |               |           |           | Go       | Clear |       |
|               |                          | Limits  | Preview/Index | History   | Clipboard | Details  |       |       |

Display Abstract Show: 20 Sort Send to Text

Entrez  
PubMed

1: Int Immunopharmacol. 2002 May;2(6):783-96.

Related Articles, Links

## Efficacy of vaccination with plasmid DNA encoding for HER2/neu or HER2/neu-eGFP fusion protein against prostate cancer in rats.

Bhattachary R, Bukkapatnam R, Prawoko I, Soto J, Morgan M, Salup RR.

PubMed  
Services

University of South Florida, Tampa 33620-5950, USA. rbhattacharjee@com1.med.usf.edu

Related  
Resources

Despite early diagnosis and improved therapy, 31,500 men will die from prostate cancer (PC) this year. The HER2/neu oncoprotein is an important effector of cell growth found in the majority of high-grade prostatic tumors and is capable of rendering immunogenicity. The antigenicity of this oncoprotein might prove useful in the development of PC vaccines. Our goal is to prove the principle that a single DNA vaccine can provide reliable immunity against PC in the MatLyLu (MLL) translational tumor model. The parental rat MatLyLu PC cell line expresses low to moderate levels of the rat neu protein. To simulate *in vivo* human PC, MatLyLu cells were transfected with a truncated sequence of human HER2/neu cDNA cloned into the pCI-neo vector. This HER2/neu cDNA sequence encodes the first 433 amino acids of the extracellular domain (ECD). MatLyLu cells were also transfected with the same HER2/neu cDNA sequence cloned into the N1-terminal sequence of EGFP reporter gene to produce a fusion protein. The partial ECD sequence of HER2/neu includes five rat major histocompatibility (MHC)-II-restricted peptides with complete human-to-rat cross-species homology. The HER2/neu protein overexpression was documented by Western Blot analysis, and the expression of fusion protein was monitored by confocal microscopy and fluorimetry. Vaccination with a single injection of HER2/neu cDNA protected 50% of animals against HER2/neu-MatLyLu tumors ( $P < 0.01$ ). When the tumor cells were engineered to express HER2/neu-EGFP fusion protein, the antitumor immunity was enhanced, as following vaccination with HER2/neu-EGFP cDNA, 80% of these rats rejected HER2/neu-EGFP-MatLyLu ( $P < 0.001$ ). Both vaccines induced HER2/neu-specific antibody titers. Rats vaccinated with EGFP-cDNA rejected 80% of EGFP-MatLyLu tumors and, interestingly, 40% of HER2/neu-MatLyLu tumors. None of the cDNA vaccines induced immunity against parental MatLyLu cells. Our data clearly demonstrate that a single injection of HER2/neu-EGFP cDNA is a very effective vaccine against PC tumors expressing the cognate tumor-associated antigen (TA). The antitumor immunity is significantly more pronounced if the tumors express xenogeneic HER2/neu-EGFP fusion protein as opposed to only the syngeneic HER2/neu oncoprotein. Our data suggests that the HER2/neu-EGFP-MatLyLu tumor is a potential animal tumor model for investigating therapeutic vaccine

strategies against PC in vivo and demonstrates the limitations of a cDNA vaccine only encoding for MHC-II-restricted HER2/neu-ECD sequence peptides.

PMID: 12095169 [PubMed - indexed for MEDLINE]

---

Display    Abstract    Show: 20    Sort    Send to    Text  

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)

Sep 4 2003 10:13:41

0